Topics

EMD Serono and Pfizer’s Phase 3 JAVELIN GASTRIC Trial Fails to Meet Primary Endpoints

10:38 EST 8 Nov 2019 | Speciality Pharma Journal

Rockland, MA and New York, US, November 8, 2019 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced topline results of the Phase III JAVELIN Gastric 100 study evaluating avelumab as first-line maintenance therapy following induction chemotherapy in patients with unresectable, …

Original Article: EMD Serono and Pfizer’s Phase 3 JAVELIN GASTRIC Trial Fails to Meet Primary Endpoints

NEXT ARTICLE

More From BioPortfolio on "EMD Serono and Pfizer’s Phase 3 JAVELIN GASTRIC Trial Fails to Meet Primary Endpoints"

Quick Search

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...